Vahl, J. M.
von Witzleben, A.
Welke, C.
Doescher, J.
Theodoraki, M. N.
Brand, M.
Schuler, P. J.
Greve, J.
Hoffmann, T. K.
Laban, S.
Article History
Received: 17 March 2021
Accepted: 9 April 2021
First Online: 20 April 2021
Declarations
:
: Simon Laban: Advisory Boards: Merck Sharp & Dohme (MSD), Bristol Myers Squibb (BMS), Astra Zeneca (AZ), Sanofi Genzyme. Honoraria: MSD, BMS, AZ, Merck Serono. Patrick Schuler: Advisory Boards: BMS, MSD. Thomas K. Hoffmann: Advisory Boards: MSD, BMS. Honoraria: MSD, BMS, Merck Serono. All other authors declared no conflict of interests, which could have influenced this work.
: Explicit informed consent and ethical approval were not required as long as this work was based on anonymized secondary data and did not influence the treatment of patients in any kind.